MBC Applying New Developments

CE / CME

Applying the Latest Developments in Metastatic Breast Cancer Through Education of Healthcare Professionals, Patients, and Caregivers

Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: October 19, 2023

Expiration: October 18, 2024

Joyce O'Shaughnessy
Joyce O'Shaughnessy, MD

Activity

Progress
1
Course Completed

Ongoing Trials of Interest in ABC

There are many ongoing trials of interest for MBC. In early disease, at the top of the table, T-DXd is being compared head-to-head against T-DM1 in the adjuvant setting in patients with HER2-positive breast cancer and residual disease after preoperative therapy (NCT04622319; DESTINY-Breast05). Dato-DXd also is being compared head-to-head against capecitabine, each in combination with a checkpoint inhibitor in patients with TNBC and residual disease after preoperative therapy (NCT05629585; TROPION-Breast03). The oral tyrosine kinase inhibitor tucatinib is also in a phase III trial in the adjuvant setting, where it is being evaluated in combination with T-DM1 vs T-DM1 alone in patients with residual disease (NCT04457596; CompassHER2 RD).

In the first‑line setting, we have a trial of sacituzumab govitecan in metastatic TNBC (NCT05382299; ASCENT-03). We have sacituzumab govitecan plus pembrolizumab for the PD-L1–positive population (NCT05382286; ASCENT-04). We have T-DXd with or without pertuzumab vs the CLEOPATRA regimen in patients with HER2-positive disease (NCT04784715; DESTINY-Breast09). In addition, we have dato-DXd vs treatment of physician’s choice in patients with TNBC who are PD-L1 negative (NCT05374512; TROPION-Breast02).

In the first-line setting and beyond, we have T-DXd vs treatment of physician’s choice in patients with HR-positive/HER2-negative or HER2-low disease who have received previous ET (NCT04494425; DESTINY-Breast06).

In addition, in the later-line settings, we have trials of dato-DXd (NCT05104866; TROPION-Breast01) and patritumab deruxtecan, another ADC directed against HER3 (NCT04965766; ICARUS-BREAST).

So, there is a lot of ongoing work. You can see how the ADCs are very popular, because they tend to combine superior efficacy and less toxicity than our standard agents.